Incyte (INCY) Accumulated Expenses (2010 - 2026)
Incyte's (INCY) quarterly Accumulated Expenses came in at $870.3 million in Q2 2026, up 1.54% YoY from $857.1 million in Q2 2025, and down 20.32% on a QoQ basis from $1.1 billion in Q1 2026.
Incyte (INCY) Accumulated Expenses (2010 - 2026) Analysis & Trends
Incyte (INCY) has 17 years of Accumulated Expenses data on file, last reported at $870.3 million in Q2 2026.
- Quarterly Accumulated Expenses rose 1.54% year-over-year to $870.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $870.3 million (up 1.54% YoY) and the FY2025 annual result came in at $1.0 billion, down 14.9% from the prior year.
- Accumulated Expenses fell to $870.3 million in Q2 2026, from $1.1 billion in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $1.4 billion in Q1 2025 to a low of $598.8 million in Q2 2022.
- A 5-year average of $925.2 million and a median of $902.9 million in 2023 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses soared 45.23% — and 2026, when it slipped 20.6%.
- Tracing INCY's Accumulated Expenses over 5 years: stood at $701.1 million in 2022, then soared by 33.45% to $935.6 million in 2023, then increased by 29.55% to $1.2 billion in 2024, then retreated by 14.9% to $1.0 billion in 2025, then declined by 15.63% to $870.3 million in 2026.
- The last three Accumulated Expenses figures came in at $870.3 million (Q2 2026), $1.1 billion (Q1 2026), and $1.0 billion (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Incyte | 24.15 Bn | 19.61 Bn | 1.57 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 870.31 Mn |
| Mar 31, 2026 | 1.09 Bn |
| Dec 31, 2025 | 1.03 Bn |
| Sep 30, 2025 | 948.44 Mn |
| Jun 30, 2025 | 857.09 Mn |
| Mar 31, 2025 | 1.38 Bn |
| Dec 31, 2024 | 1.21 Bn |
| Sep 30, 2024 | 1.13 Bn |
| Jun 30, 2024 | 1.03 Bn |
| Mar 31, 2024 | 1.10 Bn |
| Dec 31, 2023 | 935.57 Mn |
| Sep 30, 2023 | 820.61 Mn |
| Jun 30, 2023 | 810.85 Mn |
| Mar 31, 2023 | 825.44 Mn |
| Dec 31, 2022 | 701.05 Mn |
| Sep 30, 2022 | 699.81 Mn |
| Jun 30, 2022 | 598.81 Mn |
| Mar 31, 2022 | 609.29 Mn |
| Dec 31, 2021 | 533.60 Mn |
| Sep 30, 2021 | 481.88 Mn |